Improving mental health and quality of life for young cancer survivors and their caregivers

Development and Clinical Application of Intervention Program to Improve Mental Health and Quality of Life of Pediatric Solid Tumor Survivors and Caregivers, a Multicenter, Experimental Group, Pre-and-post Evaluation Intervention Study

Not applicable Interventional National Cancer Center, Korea · NCT06969742

This study is testing whether personalized counseling and education can improve mental health and quality of life for young cancer survivors and their caregivers during the transition from treatment to recovery.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment120 (estimated)
Ages10 Years to 24 Years
SexAll
SponsorNational Cancer Center, Korea Government
Locations3 sites (Goyang-si, Gyonggi-do and 2 other locations)
Trial IDNCT06969742 on ClinicalTrials.gov

What this trial studies

This study focuses on pediatric and adolescent patients diagnosed with solid tumors and their primary caregivers, assessing their cognitive and psycho-social functions. Following the assessment, participants will receive personalized counseling and educational sessions aimed at enhancing their mental health and overall quality of life. The interventions are delivered on a one-on-one basis to ensure tailored support. The study targets individuals in the acute-transitional survival period, which spans from active treatment to two years post-treatment.

Who should consider this trial

Good fit: Ideal candidates include individuals aged 10 to 24 who are either undergoing treatment for pediatric solid tumors or are survivors who completed treatment within the last two years.

Not a fit: Patients who have severe psycho-emotional issues requiring professional treatment or those with cognitive impairments that prevent effective participation may not benefit from this study.

Why it matters

Potential benefit: If successful, this program could significantly enhance the mental health and quality of life for young cancer survivors and their caregivers.

How similar studies have performed: Other studies have shown success in similar psycho-educational interventions for cancer patients, indicating a promising approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Those between the ages of 10 and 24, and diagnosed with pediatric solid tumor, who are undergoing treatment or survivors who have completed the treatment and the treatment end date is within 2 years.
* Parent or legal guardian who is a primary caregiver to children and adolescent patient of acute-transitional phase.
* Those whose cognitive ability is capable of verbal counseling and who agrees to the evaluation assessment.

Exclusion Criteria:

* Those who disagree to participate as a research subject.
* Those whose psycho-emotional state requires professional treatment or medical conditions precludes intervention.
* Those undergoing treatment and children and adolescent survivors of acute-transitional phase, whose prior intelligence assessment FSIQ score is less than 70. However, if the GAI score is 70 or higher, participation is possible after the principal investigator's interview, with linguistic competence taken into consideration.

Elimination Criteria:

* Those who withdraw consent of this research.
* Those who have difficulty participating due to worsening of disease or decease of patient.

Where this trial is running

Goyang-si, Gyonggi-do and 2 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Pediatric Solid Tumors
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.